November 18, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback